AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL) Stock Price, Analysis & Data
| Bid | 7.26 |
| Market Cap | 2.99B |
| Revenue (ttm) | 66.17M |
| Net Income (ttm) | -164.66M |
| Beta | 1.19 |
| EPS (ttm) | -0.54 |
| PE Ratio (ttm) | n/a |
| Forward PE | -13.65 |
| P/B (ttm) | 3.34 |
| P/S (ttm) | 45.22 |
| Earnings Date | Nov 5, 2026 |
| Ask | 11.66 |
| Volume | 17,223,620 |
| Avg. Volume (20D) | 7,555,478 |
| Open | 9.44 |
| Previous Close | 9.34 |
| Day's Range | 9.02 - 10.29 |
| 52-Week Range | 2.75 - 10.29 |
| Analyst | Strong Buy |
| Price Target | 11.5 (17.83%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...
Financial Performance
In 2025, AbCellera Biologics's revenue was 75.13M, an increase of 160.56% compared to the previous year's 28.83M. Earnings were -146.41M, a decrease of -10.1%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for ABCL stock is "Strong Buy". The 12-month stock price forecast is 11.5, which is upside of 17.83% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
47 minutes ago · Simply Wall St.
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz DealThe latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research ...
